Incyte | INCY - Gross Profit On Sales

Stock Price
99.14
Daily Change
1.40 1.43%
Monthly
9.75%
Yearly
58.22%
Q2 Forecast
92.62

Incyte reported $1.17B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agenus USD 34.2M 4.61M Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Exelixis USD 572.18M 7M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 226M 583M Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.25B 570M Dec/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025